AC
LENZ

AlphaCore Capital’s LENZ Therapeutics LENZ Stock Holding History

AlphaCore Capital’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.7K Buy
10,681
+678
+7% +$5.46K ﹤0.01% 1267
2026
Q1 		$91.5K Buy
10,003
+3
+0% +$42 ﹤0.01% 945
2025
Q4 		$160K Buy
+10,000
New +$291K ﹤0.01% 1027

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

AlphaCore Capital's LENZ Position: Q2 2026 in Review

AlphaCore Capital increased its LENZ Therapeutics (LENZ) stake by 6.8% in Q2 2026, buying an estimated $5.46K and bringing the position to 10,681 shares worth $60.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1267.

AlphaCore Capital first reported a position in LENZ in Q4 2025 and has held it in 3 quarters since. The position peaked at $160K in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • AlphaCore Capital held 10,681 shares of LENZ Therapeutics worth $60.7K as of Q2 2026.
  • AlphaCore Capital bought 678 LENZ Therapeutics shares in Q2 2026, an estimated $5.46K.
  • LENZ Therapeutics made up ﹤0.01% of AlphaCore Capital's portfolio in Q2 2026, its #1267 holding.
  • AlphaCore Capital first reported a position in LENZ Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • AlphaCore Capital's LENZ Therapeutics position peaked at $160K in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.